Literature DB >> 33465002

Staged treatment protocol for gait with hybrid assistive limb in the acute phase of patients with stroke.

Tomoyuki Ueno1, Aiki Marushima2, Hiroaki Kawamoto3, Yukiyo Shimizu1, Hiroki Watanabe2,3, Hideki Kadone3, Kayo Hiruta4, Shunsuke Yamauchi4, Ayumu Endo4, Yasushi Hada1, Hideo Tsurushima2, Eiichi Ishikawa2, Yuji Matsumaru2, Yoshiyuki Sankai3, Masashi Yamazaki5, Akira Matsumura2.   

Abstract

Hybrid Assistive Limb (HAL) is a wearable human assistant cyborg-type robot that helps lower-leg movement based on bioelectrical signals detected from the voluntary movement of the person wearing it. In this study, we developed a novel staged HAL treatment protocol for patients with acute stroke. The Regain Program for Gait with HAL (RPG-HAL) was formulated in four steps, based on the severity of limb paralysis. Twenty-one patients with acute stroke received a combination treatment of RPG-HAL and conventional rehabilitation. The feasibility and safety of RPG-HAL were evaluated based on changes in physical function and activities of daily living (ADL). RPG-HAL yielded improvement in gait speed, cadence, step length, and functional ambulation category (FAC). The effect size was >0.8 in all measurements. FAC (1.90) and Barthel Index (BI) (1.92) exhibited the highest scores. Twelve out of 14 patients with FAC 0 before RPG-HAL reached the upper FAC. Thus, earlier intervention using RPG-HAL as improving physical function, ADL, and gait ability in patients with stroke.

Entities:  

Keywords:  gait treatment; hybrid assistive limb; stroke

Mesh:

Year:  2021        PMID: 33465002     DOI: 10.1080/10400435.2020.1862361

Source DB:  PubMed          Journal:  Assist Technol        ISSN: 1040-0435


  1 in total

1.  Efficacy and Safety Study of Wearable Cyborg HAL (Hybrid Assistive Limb) in Hemiplegic Patients With Acute Stroke (EARLY GAIT Study): Protocols for a Randomized Controlled Trial.

Authors:  Hiroki Watanabe; Aiki Marushima; Hideki Kadone; Yukiyo Shimizu; Shigeki Kubota; Tenyu Hino; Masayuki Sato; Yoshiro Ito; Mikito Hayakawa; Hideo Tsurushima; Kazushi Maruo; Yasushi Hada; Eiichi Ishikawa; Yuji Matsumaru
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.